Centers for Disease Control and Prevention. Follow-up on Kaposi's sarcoma and Pneumocystis
pneumonia. MMWR Morb Mortal Wkly Rep.1981;30:409-410.
Centers for Disease Control and Prevention. AIDS in women—United States. MMWR Morb Mortal Wkly Rep.1990;39:845-846.
Hankins CA, Handley MA. HIV disease and AIDS in women: current knowledge and a research agenda. J Acquir Immune Defic Syndr.1992;5:957-971.
Spence MR, Reboli AC. Human immunodeficiency virus infection in women. Ann Intern Med.1991;115:827-829.
Smith D, Warren DL, Vlahov D.
et al. Design and baseline characteristics of the Human Immunodeficiency Virus
Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency
virus infection in US women. Am J Epidemiol.1997;146:459-469.
Barkan SE, Melnick SL, Preston-Martin S.
et al. for the WIHS Collaborative Study Group. The Women's Interagency HIV Study. Epidemiology.1998;9:117-125.
Mofenson LM, Fowler MG. Interruption of materno-fetal transmission. AIDS.1999;13(suppl A):S205-S214.
Perinatal Prevention Guidelines Available at: http://www.hivatis.org. Accessibility verified
February 2, 2001.
Guinan ME, Hardy A. Epidemiology of AIDS in women in the United States 1981 through 1986. JAMA.1987;257:2039-2042.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Vol 11. Atlanta, Ga: US Dept of Health and Human Services, Public Health
Service, Centers for Disease Control and Prevention; 1999.
Klevens RM, Fleming PL, Neal JJ.
et al. for the Mode of Transmission Study Group. Is there really a heterosexual AIDS epidemic in the United States?
findings of a multisite validation study, 1992-1995. Am J Epidemiol.1999;149:75-84.
Holmes R, Fawal H, Moon TD.
et al. Acquired immunodeficiency syndrome in Alabama: special concerns for
black women. South Med J.1997;90:697-701.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Vol 8. Atlanta, Ga: US Dept of Health and Human Services, Public Health
Service, Centers for Disease Control and Prevention; 1996.
Neal JJ, Fleming PL, Green TA, Ward JW. Trends in heterosexually acquired AIDS in the United States, 1988-1995. J Acquir Immune Defic Syndr Hum Retrovirol.1997;14:465-474.
Lindegren ML, Hanson C, Miller K.
et al. Epidemiology of human immunodeficiency virus infection in adolescents,
United States. Pediatr Infect Dis J.1994;13:525-535.
Rothenberg R, Woelfel M, Stoneburner R.
et al. Survival with the acquired immunodeficiency syndrome: experience with
5833 cases in New York City. N Engl J Med.1987;317:1297-1302.
Cozi Lepri A, Pezzotti P, Dorrucci M.
et al. HIV disease progression in 854 women and men infected through injecting
drug use and heterosexual sex and followed up to nine years from seroconversion. BMJ.1994;309:1537-1542.
Melnick SL, Sherer R, Louis TA.
et al. Survival and disease progression according to gender of patients with
HIV infection. JAMA.1994;272:1915-1921.
Weisser M, Rudin C, Battefay M.
et al. Does pregnancy influence the course of HIV infection? evidence from
two large Swiss cohort studies. J Acquir Immune Defic Syndr Hum Retrovirol.1998;17:404-410.
O'Brien WA, Hartigan PM, Martin D.
et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk
of progression to AIDS. N Engl J Med.1996;334:426-431.
Maini MK, Gilson RJ, Chavda N.
et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative
women and men. Genitourin Med.1996;72:27-31.
Prins M, Robertson JR, Brettle RP.
et al. Do gender differences in CD4 cell counts matter? AIDS.1999;13:2361-2364.
Farzadegan H, Hoover DR, Astemborski J.
et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet.1998;352:1510-1514.
Rompalo AM, Astemborski J, Schoenbaum E.
et al. Comparison of clinical manifestations of HIV infection among women
by risk group, CD4+ cell count, and HIV-1 plasma viral load. J Acquir Immune Defic Syndr Hum Retrovirol.1999;20:448-454.
Junghans C, Ledergerber B, Chan P.
et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet.1999;353:589.
Centers for Disease Control and Prevention. Report of NIH panel to define principles of therapy of HIV infection
and guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. MMWR Morb Mortal Wkly Rep.1998;47:1-82. Also available at: http://www.hivatis.org.
Accessed January 28, 2000.
Sterling TR, Lyles CM, Vlahov D.
et al. Sex differences in longitudinal human immunodeficiency virus type 1
RNA levels among seroconverters. J Infect Dis.1999;180:666-672.
Greenblatt RM, Ameli N, Grant RM.
et al. Impact of the ovulatory cycle on virologic and immunologic markers
in HIV-infected women. J Infect Dis.2000;181:82-90.
Greenberg AE, Thomas PA, Landesman SH.
et al. The spectrum of HIV-1-related disease among outpatients in New York
Kaplan JE, Hanson D, Dworkin MS.
et al. Epidemiology of human immunodeficiency virus-associated opportunistic
infections in the United States in the era of highly active antiretroviral
therapy. Clin Infect Dis.2000;30:S5-S14.
Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections
in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Morb Mortal Wkly Rep.1999;48:1-59, 61-66.
Vlahov D, Munoz A, Solomon L.
et al. Comparison of clinical manifestations of HIV infection between male
and female injecting drug users. AIDS.1994;8:819-823.
Centers for Disease Control and Prevention. Risk for cervical disease in HIV-infected women—New York City. MMWR Morb Mortal Wkly Rep.1990;39:846-849.
Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep.1992;41:1-19.
Ellerbrock TV, Chiasson MA, Bush TH.
et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected
Massad S, Ahdieh L, Benning L.
et al. Incidence and progression of cervical squamous lesions among women
with HIV: insights from the first 13,038 Pap smears of the Women's Interagency
HIV Study. From: 7th Conference on Retroviruses and Opportunistic Infections;
January 30-February 2, 2000; San Francisco, Calif. Abstract 675.
Massad LS, Riester KA, Anastos KM.
et al. Prevalence and predictors for squamous cell abnormalities in Papanicolaou
smears from women infected with HIV-1. J Acquir Immune Defic Syndr.1999;21:33-41.
Duerr A, Kieke B, Warren D.
et al. Human papilloma virus (HPV)-associated vaginal and cervical cytologic
abnormalities among women with or at risk for human immunodeficiency virus
infection. Am J Obstet Gynecol.In press.
Sun XW, Kuhn L, Ellerbrock TV.
et al. Human papillomavirus infection in women infected with the human immunodeficiency
virus. N Engl J Med.1997;337:1343-1349.
Chiasson MA, Ellerbrock TV, Bush TJ.
et al. Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial
neoplasia in women infected with the human immunodeficiency virus. Obstet Gynecol.1997;89:690-694.
Chiasson M, Kelly K, Vazquez F.
et al. Incidence of invasive cervical cancer in HIV seropositive women in
New York City. From: 2nd AIDS and Malignancy Conference; April 6-8, 1998; Bethesda,
Conley LJ, Ellerbrock TV, Bush TJ.
et al. Incidence of HPV-associated vulvovaginal lesions in HIV-infected and
uninfected women. From: 6th Conference on Retroviruses and Opportunistic Infections;
January 31-February 4, 1999; Chicago, Ill. Abstract 462.
Minkoff H, Ahdieh L, Massad S.
et al. Effect of highly active antiretroviral therapy (HAART) on cervical
cytologic changes associated with oncogenic HPV among HIV+ women. From: 7th Conference on Retroviruses and Opportunistic Infections;
January 30-February 2, 2000; San Francisco, Calif. Abstract 674.
Cu-Uvin S, Hogan JW, Warren D.
et al. Prevalence of lower genital tract infections among human immunodeficiency
virus (HIV)-seropositive and high-risk HIV-seronegative women. Clin Infect Dis.1999;29:1145-1150.
Greenblatt RM, Bacchetti P, Barkan S.
et al. Lower genital tract infections among HIV-infected and high-risk uninfected
women: findings of the Women's Interagency HIV Study (WIHS). Sex Transm Dis.1999;26:143-151.
Irwin KL, Moorman AC, O'Sullivan MJ.
et al. Influence of human immunodeficiency virus infection on pelvic inflammatory
disease. Obstet Gynecol.2000;95:525-534.
Ellerbrock TV, Wright TC, Bush TJ.
et al. Characteristics of menstruation in women infected with human immunodeficiency
virus. Obstet Gynecol.1996;87:1030-1034.
Harlow SD, Schuman P, Cohen M.
et al. Effect of HIV on menstrual cycle length. J Acquir Immune Defic Syndr.2000;24:68-75.
Centers for Disease Control and Prevention. Update: trends in AIDS incidence—United States, 1996. MMWR Morb Mortal Wkly Rep.1997;46:861-867.
Palella F, Delaney KM, Moorman AC.
et al. Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Zhou XJ, Sheiner LB, D'Aquila RT.
et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine
in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother.1999;43:121-128.
Denke M, Wilson JD. Assessment of nutritional status. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY:
McGraw-Hill Co; 1997:451.
Currier JS, Yetzer E, Potthoff A.
et al. Gender differences in adverse events on ritonavir: an analysis from
the Abbott 247 study. From: 1997 National Conference on Women and HIV/AIDS; May 4-7, 1997;
Los Angeles, Calif. Abstract 304.7.
Lichtenstein KA, Ward DJ, Delaney K.
et al. Clinical factors related to the severity of fat redistribution in the
HIV Outpatient Study (HOPS). From: 7th Conference on Retroviruses and Opportunistic Infections;
January 30-February 2, 2000; San Francisco, Calif. Abstract 23.
Lee D, Mathews WC. Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary
disease among HIV-infected patients on initial protease inhibitor therapy. From: 6th Conference on Retroviruses and Opportunistic Infections;
January 31-February 4, 1999; Chicago, Ill. Abstract 644.
Boxwell DE, Syrt BA.for the US Food and Drug Administration. Lactic acidosis in patients receiving nucleoside reverse transcriptase
inhibitors. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy;
September 26-29, 1999; San Francisco, Calif. Abstract 1284.
Dong KL, Bausserman LL, Flynn MM.
et al. Changes in body habitus and serum lipid abnormalities in HIV-positive
women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr.1999;21:107-113.
Sutinen J, Mathur-Wagh U. Changes in body shape during PI therapy in HIV+ women. From: 6th Conference on Retroviruses and Opportunistic Infections;
January 31-February 4, 1999; Chicago, Ill. Abstract 662.
Gervasoni C, Ridolfo AL, Santambrogio S.
et al. Nucleoside reverse transcriptase inhibitors associated fat redistribution
in HIV-infected women undergoing combined antiretroviral therapy. From: 6th Conference on Retroviruses and Opportunistic Infections;
January 31-February 4, 1999; Chicago, Ill. Abstract 660.
Ohmit SE, Schuman P, Schoenbaum E.
et al. Adherence to antiretroviral therapy among women in the HIV Epidemiology
Research Study (HERS) and Women's Interagency HIV Study (WIHS). From: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.
Markson L, Cunningham W, Andersen R.
et al. Who receives highly active antiretroviral therapy (HAART)? data from
a nationally representative sample. From: 6th Conference on Retroviruses and Opportunistic Infections;
January 31-February 4, 1999; Chicago, Ill. Abstract 105.
Freeman TJ, Stewart KE, DeMasi R, Saag MS. Adherence in the age of highly active antiretroviral therapy (HAART):
racial and gender differences. From: 1999 National HIV Prevention Conference; August 29-September
1, 1999; Atlanta, Ga. Abstract 649.
Klosinski LE, Brooks RN. Predictors of non-adherence to HIV combination therapies. From: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.
Moore J, Hamburger ME, Schuman P.
et al. Factors associated with adherence to antiretroviral medication by HIV-infected
women. From: 13th International AIDS Conference; July 9-14, 2000; Durban,
South Africa. Abstract WePeD4601.
Shapiro MF, Morton SC, McCaffrey DG.
et al. Variations in the care of HIV-infected adults in the United States. JAMA.1999;281:2305-2315.
Avis NE, Smith KW, Mayer K, Swislow L. Gender differences in quality of life among HIV+ men and women. From: 1997 National Conference of Women and HIV/AIDS; May 4-8, 1997;
Pasadena, Calif. Abstract 226.6.
Bozzette SA, Berry SH, Duan N.
et al. The care of HIV-infected adults in the United States. N Engl J Med.1998;339:1897-1904.
Altice FL, Brewer A, Tanguay S, Selwyn PA. Utilization of health services by HIV+ and HIV− drug injecting
prisoners. From: 10th International Conference on AIDS; August 7-12, 1994; Yokohama,
Japan. Abstract PD0522.
Turner BJ, Markson LE, McKee LJ.
et al. Health care delivery, zidovudine use, and survival of women. J Acquir Immune Defic Syndr.1994;7:1250-1262.
Solomon L, Stein M, Flynn C.
et al. Health services use by urban women with or at risk for HIV-1 infection:
the HIV Epidemiology Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol.1998;17:253-261.
Palacio H, Shiboski CH, Yelin EH.
et al. Access to and utilization of primary care services among HIV-infected
women. J Acquir Immune Defic Syndr.1999;21:293-300.
Cunningham WE, Anderson RM, Katz MH.
et al. The impact of competing subsistence needs and barriers on access to
medical care for persons with human immunodeficiency virus receiving care
in the United States. Med Care.1999;37:1270-1281.
Marx R, Katz MH, Park MS, Gurley RJ. Meeting the service needs of HIV-infected persons: is the Ryan White
CARE Act succeeding? J Acquir Immune Defic Syndr Hum Retrovirol.1997;14:44-55.
Burack JH, Barrett DC, Stall RD.
et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA.1993;270:2568-2573.
Weissman MM, Bruce ML, Leaf P.
et al. Affective disorders. In: Regeir D, Robins L, eds. Psychiatric Disorders
in America. New York, NY: Free Press; 1992:53-80.
Moore J, Schuman P, Schoenbaum E.
et al. Severe adverse life events and depressive symptoms among women with,
or at risk for, HIV infection in four cities in the United States of America. AIDS.1999;13:2459-2468.
El-Bassel N, Schilling RF, Irwin KL.
et al. Sex trading and psychological distress among women recruited from the
streets of Harlem. Am J Public Health.1997;87:66-70.
Rabkin JG, Johnson J, Lin SH.
et al. Psychopathology in male and female HIV-positive and negative injecting
drug users: longitudinal course over 3 years. AIDS.1997;11:507-515.
Vlahov D, Wientge D, Moore J.
et al. Violence among women with or at risk for HIV infection. AIDS Behav.1998;2:53-60.
Cohen M, Deaman C, Barkan S.
et al. Domestic violence and childhood sex abuse in HIV-infected women and
women at-risk for HIV. Am J Public Health.2000;90:560-565.
Fiore T, Flannigan T, Hogan J.
et al. HIV infection in families of HIV positive and negative at-risk women. AIDS Care.In press.
Lichtenstein B. Women and crack-cocaine use: a study of social networks and HIV risks
in an Alabama jail sample. Addict Res.1997;5:279-296.
Distabile P, Dubler NN, Solomon L, Klein RS.for the HER Study Group. Self-reported legal needs of women with or at risk for HIV infection. J Urban Health.1999;76:435-447.
Wilson TE, Massad LS, Riester KA.
et al. Sexual, contraceptive, and drug use behaviors of women with HIV and
those at high risk for infection: results from the Women's Interagency HIV
Moore J, Hamburger ME, Vlahov D.
et al. Longitudinal study of condom use patterns among women with or at risk
for HIV. AIDS Behav.In press.
Zierler S, Mayer K, Moore J.
et al. Sexual practices in a cohort of US women with and without human immunodeficiency
virus: HIV Epidemiology Research Study. J Am Med Womens Assoc.1999;54:79-83.
Lee LM, Wortley PM, Gray RH, Fleming PL. Reduced fertility and duration of HIV-1 infection in American women. From: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.